Monitor upcoming clinical data readouts in H1 2026 for EDG-7500 and EDG-15400, and the pivotal GRAND CANYON data in Q4 2026, which could be key value drivers for the stock.
EWTX drugs
EWTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $29.66entry
- T+1 · 9mo ago +2.63%α +3.08% · $30.44
- T+5 · 9mo ago −4.28%α −3.15% · $28.39
- T+20 · 8mo ago +6.71%α +13.11% · $31.65
- T+60 · 6mo ago +10.22%α +2.47% · $32.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Edgewise Therapeutics reported Q4 2025 financial results with a net loss of $50.2 million and $530.1 million in cash. The company highlighted near-term catalysts including upcoming data readouts for EDG-7500 in HCM (H1 2026), EDG-15400 in heart failure (H1 2026), and pivotal GRAND CANYON data for sevasemten in Becker muscular dystrophy (Q4 2026).
Key Financial Metrics
Key Facts
- Cash, cash equivalents and marketable securities: $530.1 million as of December 31, 2025
- R&D expenses: $43.6 million for Q4 2025 (up from $37.5 million in Q3)
- G&A expenses: $12.4 million for Q4 2025 (up from $9.4 million in Q3)
- Net loss: $50.2 million or $0.47 per share for Q4 2025
- Upcoming catalysts: CIRRUS-HCM 12-week data (H1 2026), EDG-15400 Phase 1 data (H1 2026), GRAND CANYON pivotal data (Q4 2026)
Financial Impact
Net loss increased to $50.2 million in Q4 2025 from $40.7 million in Q3 2025, with R&D and G&A expenses both increasing significantly
Risk Factors
- Clinical trial results may not meet expectations
- Regulatory approval risks for sevasemten
- Need for substantial additional capital to finance operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-020108 |
| Document: tm266859d1_8k.htm | 0001104659-26-020108 |
| Document: 0001104659-26-020108-index-headers.html | 0001104659-26-020108 |
| Document: 0001104659-26-020108-index.html | 0001104659-26-020108 |
| Document: 0001104659-26-020108.txt | 0001104659-26-020108 |
Track record
14 reports on EWTX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 144 Neutral 1/10 Entry $43.68 Now $43.68 +0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
- Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 6, 202614w ago 8-K Mixed 7/10 Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
- Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers